Citron Research Posts On X, "$APLS Expect A Raise Soon. Not Getting European Approval Shows How Dysfunctional Our Healthcare System Is. Citron Stands By Our Report From Last Month...."
Portfolio Pulse from Benzinga Newsdesk
Citron Research tweeted about Apellis Pharmaceuticals Inc. (APLS), suggesting that the company is expected to raise funds soon. The tweet criticizes the U.S. healthcare system's dysfunction, highlighted by APLS's failure to receive European approval for Syfovre. Citron reaffirms their previous report's stance, which was critical of Syfovre, despite analysts' expectations of a 30-35% revenue contribution from Europe.
December 14, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citron Research's tweet suggests that Apellis Pharmaceuticals may need to raise capital soon due to the lack of European approval for Syfovre, which was expected to contribute significantly to revenue.
The lack of European approval for Syfovre is a significant setback for Apellis Pharmaceuticals, as it was anticipated to be a substantial revenue driver. Citron's critical stance and the mention of a potential raise could lead to negative investor sentiment in the short term, potentially impacting the stock price negatively.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 90